Clinical trial
Safety and Efficacy Study of Copaxone Administered in Combination With…
NCT00203099 · Teva Branded Pharmaceutical Products R&D, Inc., Industry · Completed
Key facts
| NCT number | NCT00203099 |
|---|---|
| Title | Safety and Efficacy Study of Copaxone Administered in Combination With N-Acetylcysteine |
| Official title | A Pilot, Multicenter, Open-label, One-group Study to Explore the Efficacy, Tolerability and Safety of the Combination of Glatiramer Acetate (GA) and N-Acetylcysteine (NAC) in Subjects With Relapsing Remitting Multiple Sclerosis (RR-MS) |
| Lead sponsor | Teva Branded Pharmaceutical Products R&D, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Relapse Remitting Multiple Sclerosis |
| Intervention type | Drug |
| Interventions | Glatiramer Acetate, N-Acetylcysteine |
| Enrollment | 18 |
| Start date | Dec 1, 2004 |
| Primary completion | Aug 1, 2006 |
| Completion | Jun 1, 2008 |
| First posted | Sep 20, 2005 |
| Last update posted | May 14, 2012 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: